Delcath Systems, Inc. (DCTH)
Delcath Systems, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Queensbury, NY, US. The stock last traded at $16.82, down 2.35% on the session, giving a market capitalisation of $580.5M. On trailing twelve-month figures it carries a trailing P/E of 1528.64, a net margin of 0.6%. Its beta of 0.52 implies it has historically moved less than the broad market.
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
Delcath Systems, Inc. is most often compared with the following Healthcare names: